Close menu




June 5th, 2025 | 07:00 CEST

These ESG innovations really exist: Bayer, Deere & Company, Argo Living Soils

  • Agribusiness
  • fertilizer
  • Pharma
  • machinery
Photo credits: pexels.com

Sustainability is anything but boring: Companies such as Bayer and Deere & Company are scoring points with technological innovations that are more reminiscent of Elon Musk and SpaceX than specialists in seeds and agricultural machinery. The small Canadian agricultural company Argo Living Soils has even found a solution to completely revolutionize CO2-intensive processes in construction. We present the business models and take a look at the outlook for the three stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: BAYER AG NA O.N. | DE000BAY0017 , DEERE CO. DL 1 | US2441991054 , ARGO LIVING SOILS CORP | CA04018T3064

Table of contents:


    Deere & Company brings science fiction to the field

    When farmers use machines from Deere & Company to sow new seeds, the ExactShot™ system causes great amazement. Thanks to sensors and robot control, the system fertilizes with such precision that large amounts of fertilizer can be saved without having to accept lower yields. Almost even more revolutionary is the See & Spray technology: an AI-supported camera ensures that unwanted plants are treated with herbicide with pinpoint accuracy.** According to Deere itself, farmers have reduced their pesticide use by two-thirds with this technology, saving more than 8 million gallons of plant toxins. Precision approaches like those developed by Deere & Company reduce costs and protect soil, water, and endangered species.

    The smart farming systems are controlled via the John Deere Operations Center, a digital platform that provides real-time data on field conditions, machine utilization, and performance metrics. Farmers can monitor their operations via smartphone or PC and make data-driven decisions – from sowing time to harvest. This is not only efficient and reduces costs but is also sustainable. Analysts are giving Deere & Company's shares a good rating: Following the second quarter figures in May 2025, numerous banks have raised their price targets. Examples include JPMorgan (price target USD 540, Neutral), Barclays (USD 530, Overweight) and Raymond James (USD 560, Outperform).

    Bayer aims to become more innovative – Will acquisitions follow?

    Analyst opinions are more mixed when it comes to seed specialist Bayer – the consensus rating is "Hold." Those analysts who are more optimistic believe that the efficiency program launched last year will be successful. The core of the strategy is further innovation around sustainability: The Company plans to generate EUR 3.5 billion in additional revenue through new seed generations and more precise crop protection solutions that are more targeted and resource-efficient with the help of digital tools. Bayer plans to become as innovative as John Deere already is. Acquisitions also seem possible for the Leverkusen-based company.

    Argo Living Soils: Will this technology reduce our CO2 emissions?

    The Canadian company Argo Living Soils was founded with the aim of being a driver of innovation. The young company develops and produces organic products such as biofertilizers, worm compost, and other additives that make agricultural soils more fertile in a natural way. The business model focuses on the conversion of biomass into biochar. This biochar improves soil quality in agriculture and is considered a sustainable alternative to artificial fertilizers.

    But there is much more to the biochar produced by Argo Living Soils: the Company has developed a process to synthesize graphene from its biochar. This extremely stable carbon nanomaterial has a wide range of applications, such as an additive in asphalt to increase heat resistance or as a storage medium for hydrogen in energy systems. Argo Living Soils initially wants to use its graphene as an additive in construction and has already found partners for this. It recently entered into a research alliance with the technology company Graphene Leaders Canada with the aim of developing graphene nanoplatelets as an additive for ready-mixed concrete. The goals are to improve durability while reducing CO2 emissions in construction by around 20% through lower cement requirements. Argo Living Soils and its partners believe that this technology offers a significant lever for reducing CO2 emissions. According to the Karlsruhe Institute of Technology (KIT), concrete production is Germany's third-largest source of industrial greenhouse gas emissions.


    1,000% in one year: What is in it for investors?

    But does Argo Living Soils' approach also pay off for investors? Comparing the performance of Deere & Company and Bayer over a one-year period, the more innovative company John Deere is ahead with a return of 32.8% compared to Bayer, which lost 11% over the same period. The development of Argo Living Soils' share price, which rose by an incredible 1,061% over the course of a year, shows that the hunger for innovation is huge and that the market also offers excellent opportunities for small companies. Given its still low market capitalization of CAD 8.9 million and plans for the recently formed research alliance to deliver results by the end of the year, investors should keep an eye on ESG innovator Argo Living Soils. If the technology delivers what it promises, the Company is a takeover candidate – too many corporations are desperately looking for sustainable innovations.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on December 23rd, 2025 | 08:45 CET

    USD 600 billion market potential – Pfizer and Bayer are in the race, Vidac Pharma in the fast lane?

    • Biotechnology
    • Biotech
    • Pharma

    The market for cancer drugs is the largest segment within the pharmaceutical industry and currently has a volume of over USD 200 billion. According to experts, the market will already be worth USD 500 to 600 billion by 2032 or 2033. Companies such as Pfizer and Bayer are among the industry leaders. As is often the case, however, there are promising stocks from the second and third tiers beyond the blue chips. One such company is Vidac Pharma. The Company is pursuing a new, promising approach to skin cancer. Analysts attest to the shares' great potential.

    Read

    Commented by Armin Schulz on December 17th, 2025 | 07:05 CET

    How Bayer, WashTec, and Volkswagen will earn more money in the future with digitalization and AI

    • Automotive
    • carwash
    • Technology
    • Digitization
    • AI
    • Pharma
    • Electromobility

    Artificial intelligence is already generating measurable profits in industry today. In the pharmaceutical and chemical industries, it is revolutionizing research and accelerating the market launch of vital products. Mechanical and plant engineering is tapping into recurring sources of revenue with AI-based services and strengthening customer loyalty. And in the automotive industry, autonomous driving is highly popular and will shape the future. These advances prove that the productive phase of AI has begun. Three companies show how technology translates into competitive advantages and robust margins: Bayer, WashTec, and Volkswagen.

    Read

    Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET

    Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!

    • Biotechnology
    • Biotech
    • Cancer
    • Pharma

    Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.

    Read